Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals, a global leader in specialty pharmaceuticals, is headquartered in the United Kingdom. Founded in 1867, the company has established a strong presence in key operational regions, including North America and Europe. With a focus on pain management, autoimmune disorders, and critical care, Mallinckrodt is renowned for its innovative therapies and unique formulations. The company’s core products, such as specialty generics and branded medications, are designed to address complex medical needs, setting them apart in a competitive market. Notable achievements include a robust portfolio of FDA-approved treatments and a commitment to advancing patient care through research and development. As a trusted name in the pharmaceutical industry, Mallinckrodt continues to make significant strides in improving health outcomes worldwide.
DitchCarbon Score
How does Mallinckrodt Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mallinckrodt Pharmaceuticals's score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mallinckrodt Pharmaceuticals's reported carbon emissions
In 2023, Mallinckrodt Pharmaceuticals reported total carbon emissions of approximately 89,052,000 kg CO2e for Scope 1 and 74,164,000 kg CO2e for Scope 2, resulting in a combined total of about 162,999,000 kg CO2e for both scopes. This data reflects a slight decrease in Scope 1 emissions from 89,551,000 kg CO2e in 2022, while Scope 2 emissions also decreased from 82,347,000 kg CO2e in the same year. Mallinckrodt has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by the middle of this decade (2023-2025). Additionally, the company has committed to a 30% reduction in Scope 1 and Scope 2 emissions from a 2022 baseline by 2030. These targets are part of their broader sustainability strategy and demonstrate a proactive approach to addressing climate change. The emissions data is cascaded from Mallinckrodt Pharmaceuticals Limited, which operates under the corporate family relationship with Mallinckrodt plc. The company is focused on aligning its operations with industry standards for climate action, reflecting a commitment to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mallinckrodt Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
